- Home
- NFE vs CDNA Comparison
NFE vs CDNA Comparison
Compare NFE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- CDNA
- Stock Information
- Founded
- NFE 2014
- CDNA 1998
- Country
- NFE United States
- CDNA United States
- Employees
- NFE N/A
- CDNA N/A
- Industry
- NFE Oil/Gas Transmission
- CDNA Medical Specialities
- Sector
- NFE Utilities
- CDNA Health Care
- Exchange
- NFE Nasdaq
- CDNA Nasdaq
- Market Cap
- NFE 773.2M
- CDNA 712.2M
- IPO Year
- NFE 2019
- CDNA 2014
- Fundamental
- Price
- NFE $2.45
- CDNA $13.82
- Analyst Decision
- NFE Strong Buy
- CDNA Buy
- Analyst Count
- NFE 6
- CDNA 7
- Target Price
- NFE $8.92
- CDNA $27.67
- AVG Volume (30 Days)
- NFE 6.5M
- CDNA 1.5M
- Earning Date
- NFE 11-06-2025
- CDNA 11-03-2025
- Dividend Yield
- NFE N/A
- CDNA N/A
- EPS Growth
- NFE N/A
- CDNA N/A
- EPS
- NFE N/A
- CDNA 1.00
- Revenue
- NFE $2,008,012,000.00
- CDNA $340,826,000.00
- Revenue This Year
- NFE $7.43
- CDNA $13.02
- Revenue Next Year
- NFE $8.38
- CDNA $12.85
- P/E Ratio
- NFE N/A
- CDNA $13.85
- Revenue Growth
- NFE N/A
- CDNA 14.72
- 52 Week Low
- NFE $2.01
- CDNA $10.96
- 52 Week High
- NFE $16.66
- CDNA $32.97
- Technical
- Relative Strength Index (RSI)
- NFE 43.46
- CDNA 54.96
- Support Level
- NFE $2.23
- CDNA $12.37
- Resistance Level
- NFE $2.76
- CDNA $14.20
- Average True Range (ATR)
- NFE 0.20
- CDNA 0.73
- MACD
- NFE 0.03
- CDNA 0.27
- Stochastic Oscillator
- NFE 40.91
- CDNA 87.02
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.